Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (473)	5/11/2004 11:46:40 AM
From: zeta1961	Read Replies (1) \| Respond to of 496

Thanks Miljenko...I'm particularly interested because I worked many years in the Pedi ICU and ER...but it's been a couple of years... Midazolam made by Roche as you know has huge penetration...for sedative...but it's a benzodiazapine with its problems of tolerance, abuse... Propofol...non-benzo, minimal to no issues with abuse...and a very attractive aspect for ICU for its property of decreasing intracranial pressure...a big problem in ICU's treating head trauma and cerebral edema from other causes...midazolam does not have this property...except if Increased ICP is related to agitation... Although not as experienced in trial design as you...yesterday's call left me wondering whether they are proceeding in a manner for success of this Aquavan study...I'm trying to dig for PK for Aquavan to see if it also decreases ICP...if so, this will be very attractive...I also don't know what Roche and other anesthesia companies are doing and how far they are in trials.... The next time I talk with one of my ICU friends, I'll ask...doesn't seem to be any catalysts for rushing in here... maripoisoncenter.com old summary of propofol by a pediatrian... Regards, Zeta